logo
logo
Sign in

Global Apixaban Market Geographically Analysis

avatar
Ben Wood
Global Apixaban Market Geographically Analysis

Geographically, North America is the largest market for apixaban, accounting for more than 40% of the global market share in 2020. This is attributed to the high prevalence of cardiovascular diseases in the region and the growing adoption of NOACs over traditional anticoagulants. Europe is the second-largest market for apixaban, followed by the Asia Pacific region.

The Apixaban market is anticipated to expand as venous thromboembolism-related conditions become more common. For instance, the 2014 facts from the International Society on Thrombosis and Haemostasis showed that low, middle, and high income countries all experience about 10 million cases of venous thromboembolism each year. Additionally, expanding therapeutic uses for apixaban are anticipated to spur market expansion. As an illustration, the U.S. Food and Drug Administration approved Eliquis in 2014 for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for lowering the risk of recurrent PE and DVT after initial therapy.


The apixaban market is also benefiting from the expanding use of NOACs in indications beyond AF, such as DVT and PE. DVT occurs when a blood clot forms in a deep vein, usually in the leg, while PE occurs when a blood clot travels to the lungs. Both conditions can be life-threatening and require prompt treatment with anticoagulants such as apixaban. The growing awareness of the benefits of NOACs in these indications is expected to drive the growth of the apixaban market in the coming years.

The apixaban market is highly competitive, with several other NOACs available in the market, including rivaroxaban (Xarelto) and dabigatran (Pradaxa). However, apixaban has several advantages over these drugs, including a lower risk of bleeding and a more convenient dosing regimen. Apixaban is taken twice daily for the first 7 days after DVT or PE diagnosis, followed by once-daily dosing thereafter. In contrast, rivaroxaban requires once-daily dosing for both DVT and PE, while dabigatran requires twice-daily dosing for DVT and PE.



Read More:

https://knackersblogger.blogspot.com/2023/02/apixaban-market-size-share-outlook-and.html


collect
0
avatar
Ben Wood
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more